Literature DB >> 9646891

Nicotinic receptor desensitization and sensory gating deficits in schizophrenia.

J M Griffith1, J E O'Neill, F Petty, D Garver, D Young, R Freedman.   

Abstract

BACKGROUND: Nicotinic receptor dysfunction is a possible mechanism of the abnormal sensory gating observed in schizophrenia with the P50 auditory event-related potential. Although nicotinic receptors normally desensitize after activation by acetylcholine or nicotine, pathologically increased desensitization might cause receptor dysfunction in schizophrenia. To examine this possibility, central cholinergic neuronal activity was diminished by allowing schizophrenic patients to sleep briefly, after which they experienced a transient period of normal P50 gating, consistent with receptor resensitization during the absence of cholinergic stimulation. A critical test of the mechanism is whether this resensitization is blocked by concurrent administration of nicotine, which would provide continuous receptor stimulation.
METHODS: Six schizophrenic patients repeated the sleep experiment during nicotine exposure from a dermal patch, in a double-blind, placebo-controlled design.
RESULTS: The normalization of P50 gating immediately postsleep was replicated in the placebo arm, but this effect was decreased in all six patients during exposure to nicotine.
CONCLUSIONS: The results suggest that nicotinic receptor desensitization is responsible for the loss of P50 gating in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9646891     DOI: 10.1016/s0006-3223(97)00362-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  24 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Tobacco craving in smokers with and without schizophrenia.

Authors:  Suzanne Lo; Stephen J Heishman; Heather Raley; Katherine Wright; Heidi J Wehring; Eric T Moolchan; Stephanie Feldman; Fang Liu; Robert P McMahon; Charles M Richardson; Deanna L Kelly
Journal:  Schizophr Res       Date:  2010-07-15       Impact factor: 4.939

4.  Electroencephalography (EEG) and event-related potentials (ERPs) with human participants.

Authors:  Gregory A Light; Lisa E Williams; Falk Minow; Joyce Sprock; Anthony Rissling; Richard Sharp; Neal R Swerdlow; David L Braff
Journal:  Curr Protoc Neurosci       Date:  2010-07

Review 5.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

7.  Cognitive performance and cigarette smoking in first-episode psychosis.

Authors:  Arantzazu Zabala; José Ignacio Eguiluz; Rafael Segarra; Sonsoles Enjuto; Jesús Ezcurra; Ana González Pinto; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-26       Impact factor: 5.270

8.  Open-Label Study of Craving in Smokers With Schizophrenia Using Nicotine Nasal Spray Compared to Nicotine Patch.

Authors:  Jill M Williams; Kunal K Gandhi; Maria Katsamanis Karavidas; Marc L Steinberg; Shou-En Lu; Jonathan Foulds
Journal:  J Dual Diagn       Date:  2008-10-01

Review 9.  Recent advances in treating cognitive impairment in schizophrenia.

Authors:  Cherrie Galletly
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

Review 10.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.